Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04199767
PHASE2

SNIFF Multi-Device Study 2

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.

Official title: SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness

Key Details

Gender

All

Age Range

55 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

13

Start Date

2020-07-16

Completion Date

2020-11-03

Last Updated

2026-10-07

Healthy Volunteers

Yes

Interventions

DRUG

20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)

Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.

DRUG

40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)

Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.

Locations (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States